| G - Genito Urinary System and Sex Hormones | | |
|
| G03 - Sex Hormones and Modulators Of The Genital System | Other hormones, see H - Systemic hormonal preparations, excl. sex hormones and insulins.
Sex hormones used only in the treatment of neoplastic diseases (often selected strengths) are classified in L - Antineoplastic and immunomodulating agents.
| The DDDs of many of the hormone preparations may vary considerably with the route of administration due to substantial differences in bioavailability. The DDDs of depot preparations are calculated as the dose divided by the dosing interval.
|
|
| G03X - Other Sex Hormones and Modulators Of The Genital System | This group comprises drugs modifying the genital functions, which cannot be classified in the preceding groups.
Tibolone is classified in G03DC.
|
|
| G03XB - Progesterone Receptor Modulators | Mifepristone indicated for Cushingss syndrome is also classified in this group.
The combination package of mifepristone tablet and misoprostol vaginal tablets is classified in G03XB51.
| The DDD for mifepristone (G03XB01) and for the combination package of mifepristone tablet and misoprostol vaginal tablets (G03XB51) is based on the use in termination of pregnancy.
The DDD for the combination package is given as amount of mifepristone.
|
|
| G03XB01 - Mifepristone | | Dose | Route of administration | Note |
|---|
| | O | |
|
|
